Thanks for this @thevinnys. .....
When it comes to medical or psychiatric reports I've learned to be sceptical about business evaluations of studies. You know how bubbles can grow without substantive evidence.
So I've always had a preference for clinical studies and trials. This is the sort of thing to which the FDA would pay close attention.
I have 4 links for you and others on the matter.Abstract
https://pubmed.ncbi.nlm.nih.gov/32098487/Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders.
Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on "psilocybin," "lysergic acid diethylamide," "LSD," "ayahuasca," "3,4-methylenedioxymethamphetamine," and "MDMA," in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms "clinical trial," "therapy," or "imaging" in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care.
Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as "breakthrough therapies" for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders.
Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
This offers the best overview as published on 26 Feb 2020.
Next is https://theconversation.com/ptsd-and-psychoactive-drugs-mdma-treatment-shows-potential-but-others-lack-evidence-146092 and was published Sept 2020 and was written by the author of a system review of the available literature focusing on PTSD.
https://icahn.mssm.edu/research/center-psychedelic-psychotherapy-trauma-research/research-clinical-trials
and
https://pro.psycom.net/psychopharmacology/psychedelic-assisted-therapy-ptsd-depression
are institutes which seem to have an interest in establishing studies and both say that phase 2 and 3 trials have yet to receive approval as the principle evidence so far is 'observational' and lacking in empirical substance.
I honestly don't mean to rain on the parade and I'm not into manipulating ppl's sentiment on any co. I share the enthusiasm for conducting research. I also admit there is sufficient evidence to warrant such research.
I maintain scepticism however until research shows clear and significant results..... in the reports from researchers.